J.P. Morgan — Valuation, Funding & Investors

We're still building this profile — here is what Pulse has covered.

Latest Pulse

Aug 3, 2026BlossomHill Files for $100M Nasdaq IPO in Cancer DrugsBlossomHill Therapeutics filed for a $100M Nasdaq IPO under ticker BLSM, adding an oncology-focused biotech with $257M in prior funding to a summer pipeline of clinical-stage listings led by J.P. Morgan, Leerink and Guggenheim.→

Coverage Timeline

newest first

Aug 3, 2026IPOBlossomHill Files for $100M Nasdaq IPO in Cancer Drugs$100M IPO target→

All Coverage

IPO· Aug 3, 2026

BlossomHill Files for $100M Nasdaq IPO in Cancer Drugs

IPO$100M IPO target

BlossomHill Files for $100M Nasdaq IPO in Cancer Drugs

BlossomHill Therapeutics filed for a $100M Nasdaq IPO under ticker BLSM, adding an oncology-focused biotech with $257M in prior funding to a summer pipeline of clinical-stage listings led by J.P. Morgan, Leerink and Guggenheim.

Aug 3, 2026